Is Edesa Biotech, Inc. overvalued or undervalued?

As of 6 February 2017, the valuation grade for Edesa Biotech, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. Based on the current analysis, the company appears to be overvalued. Key ratios include a price-to-book value of 0.83, an EV to EBIT of 0.16, and an EV to EBITDA of 0.17, all of which suggest that the company's valuation metrics are not supportive of a strong investment case.
In comparison to its peers, Edesa Biotech's valuation is notably weaker, with NanoViricides, Inc. also classified as does not qualify but with a slightly worse EV to EBITDA of -2.0886, while Lisata Therapeutics, Inc. is rated risky with an EV to EBITDA of 0.2364. The negative return trends for Edesa Biotech, particularly a 54.34% decline over the past year compared to a 10.26% gain in the S&P 500, further reinforce the notion that the stock is not positioned favorably in the market.